Literature DB >> 3538547

Renal transplantation in 45 patients with amyloidosis.

A Pasternack, J Ahonen, B Kuhlbäck.   

Abstract

The results of renal transplantation in patients with amyloidosis were studied in 45 patients receiving primary cadaver grafts at a single center between March 1973 and October 1981. A control group of 45 patients with glomerulonephritis receiving primary cadaver grafts during the same period was also studied. These were matched according to the number of A and B locus incompatibilities and the date of transplantation. The 3-year survival of the patients with amyloidosis was statistically significantly inferior (51%) to that of the controls (79%). Age over 40 years was the major factor determining low survival in these patients. Mortality was concentrated in the early posttransplantation period. The 3-year graft survival rate was the same in amyloidotics (38%) and controls (45%); with death of patients not included in graft loss, the corresponding figures were 53% and 49%. Appearance of amyloid in the transplant was established by biopsy in four patients at 11-37 months of follow-up. Renal transplants functioning for more than one year were calculated to incur a minimum risk of 20% of acquiring amyloid.

Entities:  

Mesh:

Year:  1986        PMID: 3538547     DOI: 10.1097/00007890-198612000-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation.

Authors:  Greg Knoll; Sandra Cockfield; Tom Blydt-Hansen; Dana Baran; Bryce Kiberd; David Landsberg; David Rush; Edward Cole
Journal:  CMAJ       Date:  2005-11-08       Impact factor: 8.262

2.  Renal transplantation in amyloid nephropathy.

Authors:  P Heering; B Kutkuhn; H Frenzel; R P Linke; B Grabensee
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

3.  Report on 59 patients with renal amyloidosis.

Authors:  S Paydas
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

4.  Suitability for Kidney Transplantation in AL Amyloidosis: A Survey Study of Transplant and Amyloidosis Physicians.

Authors:  Robert Lam; Mary Ann Lim; Laura M Dember
Journal:  Kidney360       Date:  2021-10-14

Review 5.  Transplant Onconephrology in Patients With Kidney Transplants.

Authors:  Naoka Murakami; Allison B Webber; Vinay Nair
Journal:  Adv Chronic Kidney Dis       Date:  2022-03       Impact factor: 4.305

6.  Renal replacement therapy in multiple myeloma and systemic amyloidosis.

Authors:  J H Brown; A P Maxwell; I Bruce; B G Murphy; C C Doherty
Journal:  Ir J Med Sci       Date:  1993-06       Impact factor: 1.568

Review 7.  Renal replacement therapy in multiple myeloma and systemic amyloidosis.

Authors:  J H Brown; C C Doherty
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

Review 8.  Recurrent primary disease and de novo nephritis following renal transplantation.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

9.  Outcome of 121 patients with renal amyloid a amyloidosis.

Authors:  Elbis Ahbap; Ekrem Kara; Tuncay Sahutoglu; Taner Basturk; Yener Koc; Tamer Sakaci; Mustafa Sevinc; Cuneyt Akgol; Zuhal Atan Ucar; Arzu Ozdemir Kayalar; Feyza Bayraktar; Ayse Aysim Ozagari; Abdulkadir Unsal
Journal:  J Res Med Sci       Date:  2014-07       Impact factor: 1.852

10.  Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.

Authors:  Andrea Havasi; Cihan Heybeli; Nelson Leung; Avital Angel-Korman; Vaishali Sanchorawala; Oliver Cohen; Ashutosh Wechalekar; Frank Bridoux; Insara Jaffer; Victoria Gutgarts; Hani Hassoun; Maya Levinson; Cara Rosenbaum; Paolo Milani; Giovanni Palladini; Giampaolo Merlini; Ute Hegenbart; Stefan Schönland; Kaya Veelken; Alexander Pogrebinsky; Gheorghe Doros; Heather Landau
Journal:  Blood Cancer J       Date:  2022-08-18       Impact factor: 9.812

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.